Book a Meeting

Anti-Interleukin 23 Antibody, Non-Fucosylated (BioBet-1084ZP) (CAT#: BioBet-1084ZP) Datasheet

Target
Interleukin 23
Isotype
IgG
Description
Anti-Interleukin 23 Antibody, Non-Fucosylated (BioBet-1084ZP) is a human monoclonal IgG antibody against Interleukin 23. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Crohn's Disease; Psoriasis
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Interleukin 23 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IL-23
Full Name
Interleukin 23
Background
Interleukin-23 also known as IL-23 is a heterodimeric cytokine composed of an IL-12p40 subunit that is shared with IL-12 and the IL-23p19 subunit. A functional receptor for IL-23 (the IL-23 receptor) has been identified and is composed of IL-12R β1 and IL-23R.
Alternative Names
IL-23; Interleukin 23; IL12B; IL23A
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IL23A include Multiple Sclerosis and Inflammatory Bowel Disease.
Related Pathways
Its related pathways are Tuberculosis and PEDF Induced Signaling
Function
Combined with IL12B to form IL-23 interleukin, which is a heterodimeric cytokine that plays a role in innate immunity and adaptive immunity. IL-23 and IL-17 may constitute an acute response to surrounding tissue infection. IL-23 binds to the heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory instead of naive T cells, and promotes the production of pro-inflammatory cytokines. IL-23 induces autoimmune inflammation, so it may be the cause of autoimmune inflammatory diseases and may be important for tumor occurrence.
Post-translational modifications
No Post-translational modifications
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1084ZP
Host
Human
Species Reactivity
Human
Description
AMG 139 is a human anti-IL-23 antibody currently in a phase II trial for treating Crohn's disease. To support its clinical development in humans, in vitro assays and in vivo studies were conducted in cynomolgus monkeys to determine the pharmacology, preclinical characteristics and safety of this monoclonal antibody.
Antibody Indication
Crohn's Disease; Psoriasis

Crohn's Disease; Psoriasis

Related Products

Anti-Interleukin 23 Antibody, Non-Fucosylated (BioBet-1085ZP) (CAT#: BioBet-1085ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.